Chellappan, Dinesh KumarBhandare, Richie R.Shaik, Afzal B.Prasad, KrishnaSuhaimi, Nurfatihah Azlyna AhmadYap, Wei ShengDas, ArpitaBanerjee, PradiptaGhosh, NandiniGuith, TannerDas, AmitavaBalakrishnan, SarannyaCandasamy, MayurenMayuren, JayashreePalaniveloo, KishnethGupta, GauravSingh, Sachin KumarDua, Kamal2023-08-032023-08-032022-08-22Chellappan DK, Bhandare RR, Shaik AB, et al. Vaccine for Diabetes-Where Do We Stand?. Int J Mol Sci. 2022;23(16):9470. Published 2022 Aug 22. doi:10.3390/ijms23169470https://hdl.handle.net/1805/34708Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.en-USAttribution 4.0 InternationalDiabetesVaccinesClinical trialsInsulinGLPArticle